Prediction of antibiotic resistance phenotypes from whole genome sequencing data by 21 machine learning methods has been proposed as a promising platform for the 22 development of sequence-based diagnostics. However, there has been no systematic 23 evaluation of factors that may influence performance of such models, how they might 24 apply to and vary across clinical populations, and what the implications might be in the 25 clinical setting. Here, we performed a meta-analysis of seven large Neisseria 26 gonorrhoeae datasets, as well as Klebsiella pneumoniae and Acinetobacter baumannii 27 datasets, with whole genome sequence data and antibiotic susceptibility phenotypes 28 using set covering machine classification, random forest classification, and random forest 29 regression models to predict resistance phenotypes from genotype. We demonstrate how 30 model performance varies by drug, dataset, resistance metric, and species, reflecting the 31 complexities of generating clinically relevant conclusions from machine learning-derived 32 models. Our findings underscore the importance of incorporating relevant biological and 33 epidemiological knowledge into model design and assessment and suggest that doing so 34 can inform tailored modeling for individual drugs, pathogens, and clinical populations. We 35 further suggest that continued comprehensive sampling and incorporation of up-to-date 36 whole genome sequence data, resistance phenotypes, and treatment outcome data into 37 model training will be crucial to the clinical utility and sustainability of machine learning-38 based molecular diagnostics. 
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Molecular assays offer improved speed compared to gold-standard phenotypic 70 tests and are of particular interest because of their promise of high accuracy for the 71 prediction of AMR phenotype based on genotype (2, 3). Approaches for predicting 72 resistance phenotypes from genetic features include direct association (i.e., using the 73 presence or absence of genetic variants known to be associated with resistance to infer 74 a resistance phenotype) and the application of predictive models derived from machine 75 learning (ML) algorithms. Direct association approaches can offer simple, inexpensive, 76 and often highly accurate resistance assays for some drugs/species (2) and may even 77 provide more reliable predictions of resistance phenotype than phenotypic testing (4-6). 78
However, these approaches are limited by the availability of well-curated and up-to-date 79 panels of resistance variants, as well as the diversity and complexity of resistance 80 mechanisms. ML strategies can facilitate modeling of more complex, diverse, and/or 81 under-characterized resistance mechanisms, thus outperforming direct association for 82 many drugs/species (7-9). With the increasing speed and decreasing cost of sequencing 83 and computation, ML approaches can be applied to genome-wide feature sets (8, 10-18), 84 ideally obviating the need for comprehensive a priori knowledge of resistance loci. 85
While prediction of antibiotic resistance phenotypes from ML-derived models 86 based on genomic features has become increasingly prominent as a promising diagnostic 87 MICs that were £2 doubling dilutions of the NS breakpoints from the aggregate 156 gonococcal dataset (Table S6) yielded AZM MIC distributions similar to those of CIP (Fig  157   S1a-b) . Analysis of this restricted dataset resulted in higher performance of SCM and RF 158 AZM NS classifiers compared to those trained and tested on the full aggregate 159 gonococcal dataset (Fig S1c) . However, bACC of AZM classifiers trained and tested on 160 the restricted datasets was still significantly lower than bACC of the CIP NS classifiers (P 161 < 0.0001 and P < 0.003 for classifiers based on the EUCAST and CLSI breakpoints, 162 respectively), suggesting that both MIC distribution and additional drug-specific factors 163 can influence performance of resistance classifiers. 164
165
Sampling bias in training and testing data skews resistance model performance. 166
The diversity of resistance mechanisms for AZM in gonococci offers an opportunity to 167 evaluate the effects of sampling bias on model performance. The sampling frames for the 168 seven gonococcal datasets ranged geographically from citywide to international and 169 temporally from a single year to >20 years, and several datasets were enriched for AZM 170 resistance (11, 29) ( Table 1) . The distributions of both AZM MICs and known resistance 171 mechanisms across datasets (Fig 1b, Table S2 ) and the variable performance of AZM 172 resistance models across datasets (Table S5) suggest that AZM resistance mechanisms 173 performance of many SCM and RF-based AZM classifiers on training data compared to 175 test sets (Table S5) suggests that potentially due to a lack of signal, AZM models are 176 incorporating substantial noise or confounding factors, which may be population-specific. 177
To assess the impact of sampling on model reliability, the performance of RF classifiers 178 in prediction of AZM NS phenotypes were compared across multiple training and testing 179 sets. These include classifiers trained on subsamples of isolates from a single dataset, 180
classifiers trained on the aggregate gonococcal dataset, and classifiers trained on the 181 aggregate gonococcal dataset excluding isolates from the same dataset as the testing 182 set (Table S6 ). Given the low representation of AZM NS strains by the CLSI breakpoint 183 in many datasets, these analyses were only performed using the EUCAST breakpoint. 184
While it may be assumed that increased availability of paired genomic and 185 phenotypic resistance data from a broader range of clinical populations will facilitate more 186 accurate and reliable modeling (30), our results demonstrate that in predicting AZM 187 resistance phenotypes for isolates from most datasets (with the exception of datasets 2 188 and 5), performance of classifiers trained on the aggregate dataset was not significantly 189 better than performance of classifiers trained only on isolates from the dataset from which 190 the test isolates were derived (P < 0.0001 and P = 0.002 for datasets 2 and 5, 191 respectively, P = 0.008 for dataset 3, where the classifiers trained on the aggregate 192 dataset had lower bACC than classifiers trained only on isolates from dataset 3, and P > 193 0.234 for all other datasets , Fig 2a) . Further, there was substantial variation in 194 performance of models trained on the aggregate dataset across testing sets, with models 195 achieving significantly higher bACC for strains from datasets 3 and 4 than for strains from 196 datasets ( Table 1) . Additionally, with the exception of dataset 5, performance of AZM 198 resistance classifiers trained only on isolates from the dataset from which the test isolates 199 were derived was significantly higher than performance of classifiers trained on the 200 aggregate dataset excluding isolates from the test dataset (P = 0.537 for dataset 5, P < 201 0.0005 for all other datasets , Fig 2a) . 202
Performance of RF classifiers trained and tested on dataset 2 was limited by low 203 specificity, which was improved in models trained on the aggregate dataset (Fig 2b) . The 204 low specificity achieved by RF classifiers trained and tested on this dataset is likely due 205 to the low representation of S strains, most of which were within one doubling dilution of 206 the NS breakpoint (Fig 2c) , and thus the more comprehensive representation of negative 207 (S) data in the aggregate training set was associated with improved specificity. 208
Conversely, performance of RF classifiers trained and tested on dataset 5 was more 209 limited by low sensitivity, which was improved in models trained on the aggregate dataset 210 (Fig 2b) . This dataset had a low representation of strains with high AZM MICs (Fig 2d) , 211 and thus the more comprehensive representation of positive (NS) data in the aggregate 212 training set was associated with improved sensitivity in predicting AZM NS for these 213 strains. For both SCM and RF-C AZM resistance models across all datasets, there was 214 a significant positive correlation between the ratio of model sensitivity to model specificity 215 and the ratio of NS to S strains in the dataset (Pearson r > 0.98, P < 0.0001 [Pearson 216 correlation] for both SCM and RF-C, Fig S2a) . 217
On the other hand, while representation of strains with higher AZM MICs was also 218 observed in other datasets (i.e., datasets 1, 6, and 7) and was similarly reflected in the 219 (Table S5) , AZM NS prediction accuracy for strains from these datasets was not improved 221 by training classifiers on the aggregate dataset. Further, even after down-sampling two 222 of the datasets with the most disparate MIC distributions, sample sizes, and model 223 performance (datasets 2 and 4) such that the number of strains and AZM MIC 224 distributions were identical between the two datasets (Fig S2b) , there was still a 225 significant difference in AZM NS prediction accuracy of models trained and tested on 226 these different datasets (Fig S2c, P < 0 .004). Together, these results demonstrate that 227 resistance model performance may be strongly associated with the distributions of both 228 resistance phenotypes and genetic features and thus can be highly population-specific. 229 230 ML prediction models of antibiotic susceptibility / non-susceptibility outperform 231
MIC models 232
Gonococcal CIP and AZM MICs were dichotomized by both EUCAST and CLSI 233 breakpoints to assess the impact of variation in MIC breakpoints on model performance. 234
As the EUCAST and CLSI breakpoints for CIP in gonococci are within a single doubling 235 dilution and the vast majority of isolates have much lower or higher CIP MICs (Fig 1a) , 236 >99% of isolates in the aggregate dataset were consistently S or NS by both breakpoints. 237
Of the 23 isolates with MICs between the two breakpoints, 18 had MICs derived from 238
Etests of 0.032 µg/mL or 0.047 µg/mL, making their classification relative to the EUCAST 239 breakpoint of 0.03 µg/mL ambiguous. In contrast, the EUCAST and CLSI breakpoints for 240 AZM in gonococci are separated by two doubling dilutions, and for many isolates, the 241 AZM MIC was within this range (Fig 1b) . As such, only 67% of isolates in the aggregate 242 dataset were consistently S or NS by both breakpoints. CIP NS classifier performance 243 was either identical or nearly identical for both breakpoints in the aggregate and most 244 individual gonococcal datasets (Fig 3a) . In contrast, the bACC of AZM NS prediction by 245 both SCM and RF classifiers based on the CLSI breakpoint was significantly higher than 246 for those based on the EUCAST breakpoint across all gonococcal datasets assessed by 247 both breakpoints (P < 0.0001, Fig 3b) . 248
To assess the performance of MIC prediction models relative to binary S/NS 249 resistance phenotype classifiers, RF-mC and RF-R models were trained and evaluated 250 for CIP and AZM MIC prediction in gonococci. Average exact match rates between 251 predicted and phenotypic MICs ranged from 64-86% and 54-78% by RF-mC and RF-R, 252
respectively, for CIP, and from 24-60% and 45-65%, respectively, for AZM (Tables S4-253
S5). Average 1-tier accuracies (the percentage of isolates with predicted MICs within one 254
doubling dilution of phenotypic MICs) were substantially higher but also varied widely 255 across datasets and between the two MIC prediction methods (ranging from 82%-96% 256 and 76-87% by RF-mC and RF-R, respectively, for CIP, and from 73-94% and 73-83%, 257 respectively, for AZM; Tables S4-S5 ). There was no consistent or significant relationship 258 across the different datasets between MIC prediction accuracy (exact match or 1-tier 259 accuracy) and bACC for either drug by either MIC prediction method (Fig 3c-f) . Further, 260 for both drugs by both breakpoints in the aggregate gonococcal dataset, binary RF-C 261 models had equivalent or significantly higher bACC than RF-mC and RF-R MIC prediction 262 models (P > 0.175 for AZM NS by the CLSI breakpoint by RF-C compared to RF-mC or 263 RF-R, P < 0.017 for all others, Tables S4-S5) . 264 265 resistance prediction 267 Increasing genomic diversity, or an increasing ratio of genomic features (e.g., k-mers) to 268 observations (e.g., genomes), may present an additional challenge for ML-based 269 prediction of antibiotic resistance (12). To investigate ML-based antibiotic resistance 270 prediction across species with different levels of genomic diversity, SCM and RF-C were 271 used to model CIP NS in K. pneumoniae and A. baumannii, two species with genomic 272 diversity (i.e., ratio of unique 31-mers to number of genomes) several times that of 273 gonococci (Fig 4a-b) . SCM classifiers trained on and used to predict CIP NS for K. 274 pneumoniae achieved significantly lower accuracy than all of the gonococcal datasets (P 275 Fig 4c) , while SCM classifiers trained on and used to predict CIP NS for A. 276 baumannii achieved significantly lower accuracy than gonococcal datasets 3-5 and 7 (P 277 < 0.033) and roughly equivalent accuracy to gonococcal datasets 1-2 and 6, as well as 278 the aggregate gonococcal dataset (P > 0.059, Fig 4c) . The performance of RF-C models 279 was significantly lower for both K. pneumoniae and A. baumannii compared to all 280 gonococcal datasets (P < 0.0001, Fig 4d) . 281
While the SCM classifiers for CIP NS in K. pneumoniae performed significantly 282 better on the training sets than the testing sets (Table S4, P < 0.0001), indicating that 283 these models may be overfitted, there was no significant difference between RF-C model 284 performance on training and testing sets for either K. pneumoniae or A. baumannii (P > 285 0.194), suggesting that overfitting alone cannot explain the variable classifier 286 performance across different species. Down-sampling K. pneumoniae and A. baumannii 287 to match the CIP MIC distributions of the gonococcal datasets was infeasible due to the 288 down-sampling to equalize the number of S and NS strains within each dataset (Table  290 S6, Fig. S3a-b) , performance of K. pneumoniae and A. baumannii CIP NS classifiers was 291 still significantly lower than that of gonococcal CIP NS classifiers, with the exception of 292 SCM classifiers based on the down-sampled K. pneumoniae dataset, which performed 293 roughly equivalently to SCM classifiers based on gonococcal datasets 2 and 6 (P > 0.07 294 for the SCM classifiers based on the down-sampled K. pneumoniae dataset compared to 295 SCM classifiers based on gonococcal datasets 2 and 6; P < 0.0004 for all other 296 comparisons, Figure S3c) . 297
Direct association based on GyrA codon 83 mutations (equivalent to codon 91 in 298 gonococci) alone predicted CIP NS in K. pneumoniae with 86% sensitivity and 99% 299 specificity, and thus had a marginally higher bACC (92.5%) than for the SCM classifiers 300 and a substantially higher bACC than the RF classifiers. Similarly, for A. baumannii, GyrA 301 codon 81 mutations (equivalent to codon 91 in gonococci) alone predicted CIP NS in with 302 97% sensitivity and 98% specificity, and thus with a roughly equivalent bACC (97.5%) to 303 the SCM classifiers and a substantially higher bACC than the RF classifiers. 304 305 306 Discussion 307 ML offers an opportunity to leverage WGS data to aid in development of rapid molecular 308 diagnostics. While more comprehensive sampling of methods and parameters will be 309 necessary to optimize model performance, we demonstrate that multiple factors beyond 310 ML methods and parameters can affect model performance, reliability, and 311 resistance mechanisms present challenges to ML-based prediction of resistance 313 phenotypes and that sampling frame (i.e., temporal range, geographic range, and/or 314 sampling approach) can substantially affect performance of such predictive models. We 315 demonstrated significant variability in performance and potential clinical utility of 316 predictive models based on different resistance metrics and further showed that the 317 capacity to model antibiotic resistance may be highly variable across different species. 318 319
Variable performance of ML-based resistance prediction models by antibiotic 320
Genotype-based resistance diagnostics have largely focused more on evaluating 321 the presence of resistance determinants and less on predicting the susceptibility profile 322 of a given isolate (8). However, in clinical settings where the empirical presumption is of 323 resistance, prediction that an isolate is susceptible to an antibiotic may be more important 324 in guiding treatment decisions. As such, the clinical utility of a genotype-based resistance 325 diagnostic may be determined by its capacity to accurately predict susceptibility 326 phenotype for multiple drugs. 327
While variable performance of ML-based predictive models has been observed 328 across different drugs (7, 8, 10, 11, 14, 15), it has often been attributed to dataset size 329 and/or imbalance (7, 14, 15). Further, while it is more difficult to predict resistance 330 phenotypes from genotypes for drugs that are associated with unknown, multifactorial, 331 and/or diverse resistance mechanisms than for drugs for which resistance can largely be 332 attributed to a single variant (14, 29), this caveat has been presented specifically as a 333 limitation of models based on known resistance loci in comparison to unbiased machine 334 comparing performance of predictive models based on genome-wide feature sets 336 between CIP and AZM across multiple gonococcal datasets, we showed that even with 337 relatively large and phenotypically balanced datasets, ML algorithms cannot necessarily 338 be expected to successfully model complex and/or diverse resistance mechanisms, 339 particularly given that the representation of these resistance mechanisms in training 340 datasets is a priori unknown. 341
As a high proportion of reported AZM MICs in gonococci are within 1-2 doubling 342 dilutions of the NS breakpoints, it is possible that the inferior performance of AZM 343 classifiers is partly attributable to errors and/or variations in MIC testing. However, given 344 the noise of phenotypic MIC testing even with standardized protocols (32), this may be 345 an inherent limitation of NS classifiers when low-level resistance is common. Further, 346 while we show that removing strains with MICs £2 doubling dilutions from the breakpoints 347 improved AZM classifier performance compared to AZM models trained and tested on 348 the full dataset, performance of AZM classifiers trained and tested on this restricted 349 dataset was still significantly lower than that of CIP classifiers, suggesting that additional 350 drug-specific factors, such resistance mechanism diversity and/or complexity, can 351 constrain classifier performance. GeneXpert MTB/RIF assay, reportedly accounted for <5% of TB RIF resistance in most 361
countries, but, in Swaziland was found to be present in up to 30% of MDR-TB (35)
By comparing performance of AZM NS classifiers across multiple training and 368 testing sets, we showed significant variation in performance of classifiers trained on a 369 large and diverse global collection across testing sets from different sampling frames. In 370 some cases of imbalanced datasets, models trained on datasets with a more 371 comprehensive representation of resistance phenotypes improve prediction accuracy. 372
Our results further demonstrate that the direction of dataset imbalance (i.e., the ratio of 373 NS to S strains) is significantly correlated with the direction of model performance (i.e., 374 the ratio of sensitivity to specificity), suggesting that, for example, optimizing sensitivity of 375 predictive models for drugs with low prevalence of NS strains may require substantial 376 enrichment of NS strains and/or down-sampling of S strains. However, while differential 377 classifier performance among different datasets may be partially attributable to differential 378 MIC distributions, our results also show variable classifier performance between datasets 379 even in the case of identical MIC distributions (and sample size) and further suggest that 380 significantly improve model performance, as models trained on the aggregate global 382 gonococcal dataset did not improve prediction accuracy for most datasets. 383 performance of all AZM models based on the EUCAST breakpoint compared to those 417 based on the CLSI breakpoint suggests that many isolates with AZM MICs between the 418 two breakpoints lack genetic signatures that contribute to high model performance. While 419 the clinical relevance of AZM MICs between these two breakpoints in gonococci is 420 unclear, these isolates may be more likely to be associated with AZM treatment failure 421 than isolates with lower MICs, and thus evaluation of classifiers using only higher 422 breakpoints may misrepresent their diagnostic value, particularly in the absence of 423 sufficient treatment outcome data. 424
Models that predict MICs provide more refined output than a binary classifier but 425 generally achieve low rates of exact matches between phenotypic and predicted MICs 426
testing (32) and the potential lack of discriminating genetic features between isolates with 428
MICs separated by 1-2 doubling dilutions (14), MIC prediction models may be unlikely to 429 provide much better resolution than binary S/NS classifiers. Even if MIC predictions could 430 provide additional resolution, the most important criterion of such a diagnostic would likely 431 still be its ability to correctly predict resistance phenotypes relative to a clinically relevant 432 breakpoint. Thus, performance of MIC prediction models with respect to breakpoints may 433 be the biggest determinant of their diagnostic utility. By building MIC prediction models 434 for CIP and AZM in gonococci, we observed low rates of exact matches between 435 phenotypic and predicted MICs and variable 1-tier accuracies, with no relationship 436 between 1-tier accuracy and categorical agreement (i.e., prediction accuracy relative to 437
NS breakpoints). Further, binary classifiers performed equivalently or better than MIC 438
prediction models. 439
440

ML antibiotic resistance prediction model success varies across species 441
Bacterial species with high genomic diversity (e.g., open pangenomes) present 442 additional challenges to ML-based prediction of antibiotic resistance. Increased 443 resistance mechanism complexity and greater inter-isolate variation in resistance 444 mechanisms require more intensive sampling to capture a significant portion of the 445 resistome (47). On the technical side, even for heavily sampled species, when using 446 whole genome feature sets, the number of genetic features (e.g., k-mers or SNPs) will 447 always be much larger than the number of observations (isolates), increasing the risk of (average VME and ME rates of 0.5% and 2.5%, respectively) using a decision tree-based 462 
Isolate selection and dataset preparation 480
See K. pneumoniae and A. baumannii datasets were selected based on the availability 486 of isolates collected during a single survey that were tested for CIP susceptibility and 487 whole genome sequenced using consistent platforms (in both cases, the BD-Phoenix 488 system and either Illumina MiSeq or NextSeq). 489 MIC data were obtained from the associated publications, except in the cases of 490 dataset 1 (NCBI Bioproject PRJEB10016; see Table S7 ) and dataset 9, which were 491 obtained from the NCBI BioSample database (https://www.ncbi.nlm.nih.gov/biosample). 492
Raw sequence data were downloaded from the NCBI Sequence Read Archive 493 (https://www.ncbi.nlm.nih.gov/sra). Genomes were assembled using SPAdes (48) with 494 default parameters, and assembly quality was assessed using QUAST (49). Contigs <200 495 two standard deviations of the dataset mean were removed. 497
498
Evaluation of known resistance variants 499
Previously identified genetic loci associated with reduced susceptibility to CIP or AZM in 500 gonococci are indicated in Tables S1-S2, respectively. The sequences of these loci were 501 extracted from the gonococcus genome assemblies using BLAST (50) followed by 502 MUSCLE alignment (51) to assess the presence or absence of known resistance variants. 503
The presence or absence of quinolone resistance determining mutations in gyrA was 504 similarly assessed in K. pneumoniae and A. baumannii assemblies. Presence or absence 505 of gonococcal AZM resistance mutations in the multi-copy 23S rRNA gene was assessed 506 using BWA-MEM(52) to map raw reads to a single 23S rRNA allele from the NCCP11945 507 reference isolate (NGK_rrna23s4), the Picard toolkit 508
(http://broadinstitute.github.io/picard) to identify duplicate reads, and Pilon (53) to 509 determine the mapping quality-weighted percentage of each nucleotide at the sites of 510 interest. 511 512
ML-based prediction of resistance phenotypes 513
Predictive modeling was carried out using SCM and RF algorithms, implemented in the 514 Kover (11, 12) and ranger (54) packages, respectively. K-mer profiles (abundance profiles 515 of all unique words of length k in each genome) were generated from the assembled 516 contigs using the DSK k-mer counting software (55) with k=31, a length commonly used 517 in bacterial genomic analysis (11, 12, 36, 56). For each dataset, 31-mer profiles for all 518 strains were combined using the combinekmers tool implemented in SEER (36), 519 removing 31-mers that were not present in more than one genome in the dataset. Final 520 matrices used for model training and prediction were generated by converting the 521 combined 31-mer counts for each dataset into presence/absence matrices. For each 522 SCM binary classification analysis (using S/NS phenotypes based on the two different 523 breakpoints for each drug), the best conjunctive and/or disjunctive model using a 524 maximum of five rules was selected using five-fold cross-validation, testing the suggested (http://aldro61.github.io/kover/doc_learning.html). In order to assess binary classification 528 across multiple methods, RF was also used to build binary classifiers (RF-C) using S/NS 529 phenotypes. Further, to compare performance of binary classifiers to MIC prediction 530 models, RF was used to build multi-class classification (RF-mC) and regression (RF-R) 531 models based on log 2 (MIC) data. For all RF analyses, forests were grown to 1000 trees 532 using node impurity to assess variable importance and five-fold cross-validation to 533 determine the most appropriate hyperparameters (yielding the highest bACC or 1-tier 534 accuracy for NS-or MIC-based models, respectively), testing maximum tree depths of 5, 535 10, 100, and unlimited and mtry (number of features to split at each node) values of 1000, 536 10000, and either Öp or p/3, for classification and regression models, respectively, where 537 p is the total number of features (31-mers) in the dataset. While a grid search would 538 enable assessment of more combinations of different hyperparameter values and thus 539 finer tuning of hyperparameters, such an approach is computationally prohibitive on 540 datasets of this size. To standardize reported MIC ranges across datasets, CIP MICs 541 £0.008 µg/mL or ³32 µg/mL were coded as 0.008 µg/mL or 32 µg/mL, respectively, and 542
respectively. 544
The set of SCM and RF analyses performed are indicated in Tables S3 and S6 . 545
For each of the seven individual gonococcal datasets, as well as the aggregate 546 gonococcal dataset (all gonococcal datasets combined, removing duplicate strains) and 547 the K. pneumoniae and A. baumannii datasets, training sets consisted of random sub-548 samples of two-thirds of isolates from the dataset indicated (maintaining proportions of 549 each resistance phenotype from the original dataset), while the remaining isolates were 550 used to test performance of the model. Each set of analyses (for each combination of 551 dataset/drug/resistance metric/ML algorithm) was performed on 10 replicates, each with 552 a unique randomly partitioned training and testing set. For all gonococcal datasets, 553
separate models were trained and tested using the EUCAST (57) and CLSI (58) 554 breakpoints for NS to CIP. Four of the N. gonorrhoeae datasets had insufficient (<15) NS 555 isolates by the CLSI breakpoint for AZM non-susceptibility and thus were only assessed 556 at the EUCAST AZM breakpoint. CIP MICs for the K. pneumoniae isolates were not 557 available in the range of the EUCAST breakpoint (0.25 µg/mL), and thus only the CLSI 558 breakpoint for NS (>1 µg/mL) was assessed. For A. baumannii, the EUCAST and CLSI 559 breakpoints for ciprofloxacin NS are the same (>1 µg/mL). Due to the very limited range 560 of MICs within the BD-Phoenix testing thresholds and thus the CIP MICs available for K. 561 pneumoniae and A. baumannii, predictive models based on MICs were not generated for 562 these species. For analyses in Table S6 where datasets were down-sampled to equalize 563 MIC distributions between datasets or the number of S and NS strains within datasets, 564 the required number of strains from the over-represented class(es) were selected at 565 random for removal. 566
Model performance was assessed by sensitivity (1 -VME rate), specificity (1 -ME 567 rate), and aggregate bACC (the average of the sensitivity and specificity (59)). bACC was 568 used as an aggregate measure of model performance as, unlike metrics such as raw 569 accuracy, error rate, and F1 score, it provides a balanced representation of false positive 570 and false negative rates, even in the case of dataset imbalance. For MIC prediction 571 models, the percentage of isolates with predicted MICs exactly matching the phenotypic 572
MICs (rounding to the nearest doubling dilution, in the case of regression models), as well 573 as the percentage of isolates with predicted MICs within one doubling dilution of 574 phenotypic MICs (1-tier accuracy), were also assessed. In order to account for variations 575 in MIC testing methods and thus in the dilutions assessed, criteria for exact match rates 576 and 1-tier accuracies were relaxed to include predictions within 0.5 doubling dilutions or 577 1.5 doubling dilutions, respectively, of the phenotypic MIC. Mean and 95% confidence 578 intervals for all metrics were calculated across the 10 replicates for each analysis. 579
Differential model performance between datasets or methods was evaluated by 580 comparing mean bACC between sets of replicates by two-tailed unpaired t-tests with 581
Welch's correction for unequal variance (a=0.05). Unless otherwise noted, all P-values 582 are derived from these unpaired t-tests. Relationships between MIC prediction accuracy 583 and bACC and between dataset imbalance and model performance were assessed by 584
Pearson correlation (a=0.05). Table S1 . Genetic variants previously associated with ciprofloxacin resistance in N. 844 gonorrhoeae. 845 Table S2 . Genetic variants previously associated with azithromycin resistance in N. 846 gonorrhoeae. 847 Table S3 . Summary of approach in the primary set covering machine and random forest 848 analyses. 849 Table S4 . Performance (mean with 95% confidence intervals) of predictive models for 850 ciprofloxacin resistance from the primary set covering machine and random forest 851 analyses. 852 Table S5 . Performance (mean with 95% confidence intervals) of predictive models for 853 azithromycin resistance from the primary set covering machine and random forest 854 analyses. 855 Table S6 . Summary of approach in the additional random forest analyses for assessment 856 of sampling bias. 857 Table S7 . Study ID, machine learning dataset(s), antibiotic susceptibility testing (AST) 858 methods, azithromycin (AZM) and ciprofloxacin (CIP) minimum inhibitory concentrations 859 (MICs) for all strains assessed. 860 
